Recent advances in the therapeutic applications of pyrazolines

Bibliography

• ElShora A. Crystal and molecular structure of 3-hydrazino-1-hydrazinothiocarbonyl pyrazoline (TNT3). Egypt J Sol 2000;23:251-4
   Google Scholar
• Li JT, Zhang XH, Lin ZP. An improved synthesis of 1,3,5-triaryl-2-pyrazolines in acetic acid aqueous solution under ultrasound irradiation. Beilstein J Org Chem 2007;3: (doi:10.1186/1860-5397-3-13)
   Google Scholar
• Sobhi HR, Yamini Y, Esrafili A, Adib M. Extraction and determination of 2-pyrazoline derivatives using liquid phase microextraction based on solidification of floating organic drop. J Pharm Biomed 2008;48:1059-63
   PubMed Web of Science ®Google Scholar
• Eisinger J, Boens N, Flores J. Fluorescence polarization study of human-erythrocyte membranes with 1-Phenyl-3-(2-Naphthyl)-2-Pyrazoline as orientational probe. Biochim Biophys Acta 1981;646:334-43
   PubMedGoogle Scholar
• Li JF, Guan B, Li DX, Dong C. Study on the fluorescence properties of a new intramolecular charge transfer compound 1,5-diphenyl-3-(N-ethylcarbazole-3-yl)-2-pyrazoline. Spectrochim Acta A 2007;68:404-8
   PubMed Web of Science ®Google Scholar
• oFischer E, Knevenagel O. Compounds of phenylhydrazine with acrolein, mesityloxide, and allylbromide. Justus Liebigs Ann Chem 1887;239:194-206
   Google Scholar
• Levai A. Synthesis of pyrazolines by the reactions of alpha,beta-enones with diazomethane and hydrazines (review). Chem Heterocycl Compd 1997;33:647-59
   Google Scholar
• Leavai A. Synthesis of 2-pyrazolines by the reactions of alpha,beta-unsaturated aldehydes, ketones, and esters with diazoalkanes, nitrile imines, and hydrazines. J Heterocyclic Chem 2002;39:1-13
   Google Scholar
• Farag AM, Abbas IM, Abdallah MA, Regioselective synthesis of novel 1-Methyl-2-(4-Aryl-5-Cyano-1,3-Diphenyl-4,5-Dihydropyrazol-5-Yl)benzimidazoles and 2-(4-Aryl-5-Cyano-1,3-Diphenyl-4,5-Dihydropyrazol-5-yl)benzothiazoles via benzonitrilium N-Phenylimide. J Chem Res S 1994;286-7
   Google Scholar
• Farag AM, Kheder NA, Budesinsky M. Regioselective synthesis of polysubstituted 3,3'-bi-1H-pyrazole derivatives via 1,3-dipolar cycloaddition reactions. Tetrahedron 1997;53:9293-300
   Google Scholar
• Farag AM, Shawali AS, Abed NM, Dawood KM. 1,3-Dipolar cycloaddition syntheses of 3,3'-Bi(2-Pyrazolines), 3,3'-Bipyrazoles and 3,3'-Bi(1,2,4-Triazoles). Gazz Chim Ital 1993;123:467-70
   Google Scholar
• Hassaneen HM, Algharib MS, Farag AM, Shawali AS. Direct synthesis of pyrazoles via reaction of C-ethoxycarbonyl-N-arylnitrilimines with benzalmalononitriles and some alpha-cyanocinnamic acid-derivatives. J Prakt Chem 1988;330:558-62
   Google Scholar
• Hassaneen HM, Farag AM, Algharib MS, Selectivity in cyclo-additions of nitrilimines to geminal dinitriles and alpha-beta-disubstituted acrylonitriles. Gazz Chim Ital 1988;118:569-72
   Google Scholar
• Hassaneen HM, Farag AM, Shawali AS, Algharib MS. Regioselectivity in dipolar cycloaddition reactions of N-Phenylcinnamonitrilimine. J Heterocyclic Chem 1987;24:577-80
   Google Scholar
• Shawali AS, Farag AM, Algharib MS, Albar HA. 1,3-Dipolar cycloaddition reactions of benzonitrilium N-Phenylimide with 3-Arylmethylene-5-Phenylfuran-2(3H)-ones. J Chem Res S 1993;80-1
   Google Scholar
• Kumar S, Bawa S, Drabu S, Biological activities of pyrazoline derivatives: a recent development. Recent Patents Anti Infect Drug Discov 2009;4:154-63
   PubMedGoogle Scholar
• Rahman MA, Siddiqui AA. Pyrazoline derivatives: a worthy insight into the recent advances and potential pharmacological activities. Int J Pharm Sci Drug Res 2010;2:165-75
   Google Scholar
• Marti BS, Ramon BM, Jordi LT. One-pot preparation of cinchonidine salt of (4S,5S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1Hpyrazole-3-carboxylic acid. Eur Pat Appl. EP2314578A120110427; 2011
   Google Scholar
• Yoo JU, Lee DW, Choi JG, Preparation of 3,4-diphenyl-4,5-dihydro-pyrazole-1-carboxylic acid hydrazide compounds as cannabinoid 1 (CB1) modulators. Repub Korean Kongkae Taeho Kongbo. KR2010095277A20100830; 2010
   Google Scholar
• Lambert W, Crouse G, Sparks T, Cudworth D. Pesticidal compositions of prepared heteroaryl-N-aryl carbamates and their use in pest control. Eur Pat Appl. EP2151234A120100210; 2010
   Google Scholar
• Soler Ranzani L, Casadevall Pujals G, Santanach Delisau A. Preparation of the cannabinoid CB1 receptor ligand 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(cis-2,6-dimethylpiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide and pharmaceutical formulations thereof in solid solutions and/or solid dispersions. PCT Int Appl. WO2010012437A120100204; 2010
   Google Scholar
• Mcelroy JF, Chorvat RJ. Substituted N-phenyl-5-phenyl-pyrazolin-3-yl amides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity. US20090286758A120091119; 2009
   Google Scholar
• Lange JHM, van Stuivenberg HH, Veerman W, Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity. Bioorg Med Chem Lett 2005;15:4794-8
   PubMed Web of Science ®Google Scholar
• Buschmann HH, Torrens-Jover A, Mas-Prio J, Yenes-Minguez S. Preparation of sulfonamide substituted pyrazoline compounds as CB1 modulators. PCT Int Appl. WO2008043544A120080417; 2008
   Google Scholar
• Srivastava BK, Joharapurkar A, Raval S, Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CBI receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model. J Med Chem 2007;50:5951-66
   PubMed Web of Science ®Google Scholar
• Donohue SR, Pike VW, Finnema SJ, Discovery and labeling of high-affinity 3,4-diarylpyrazolines as candidate radioligands for in vivo imaging of cannabinoid subtype-1 (CB(1)) receptors. J Med Chem 2008;51:5608-16
   PubMedGoogle Scholar
• Fisas-Escasany MA, Buschmann HH. Preparation of substituted pyrazoline for preventing weight gain. Eur Pat Appl. EP1946777A120080723; 2008
   Google Scholar
• Vela Hernandez JM, Yenes-Minguez S. Preparation of (4S,5S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(cis-2,6-dimethylpiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide as a cannabinoid CB1 neutral antagonist for treatment of food intake disorders. PCT Int Appl. WO2009124950A220091015; 2009
   Google Scholar
• Vela Hernandez JM, Yenes-Minguez S. Preparation of (4S,5S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(cis-2,6-dimethylpiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide as a cannabinoid CB1 neutral antagonist for treatment of food intake disorders. Eur Pat Appl. EP2108643A120091014; 2009
   Google Scholar
• Lange JHM, Zilaout H, Van Vliet BJ. Preparation of 5-aryl-4,5-dihydro-(1H)-pyrazoles as cannabinoid CB1 receptor agonists. PCT Int Appl. WO2009037244A220090326; 2009
   Google Scholar
• Yildirim M, Wals HC, Van Vliet BJ, Lange JHM. Preparation of 4,5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators. PCT Int Appl. WO2008152086A220081218; 2008
   Google Scholar
• Torrens-Jover A, Yenes-Minguez S. Preparation of indoline-substituted pyrazoline derivatives as cannabinoid receptor modulators. PCT Int Appl. WO2007009721A220070125; 2007
   Google Scholar
• Torrens-Jover A, Yenes-Minguez S. Preparation of azepane- or azocane-substituted pyrazoline derivatives as cannabinoid receptor modulators. PCT Int Appl. WO2007009723A2 20070125; 2007
   Google Scholar
• Buschmann H, Torrens-Jover A, Mas Prio J, Preparation of 4,5-dihydro-1H-pyrazole derivatives as cannabinoid receptor inhibitors for treating various diseases. PCT Int Appl. WO2007009689A120070125; 2007
   Google Scholar
• Torrens-Jover A, Mas Prio J, Buschmann HH, 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments. Eur Pat Appl. EP1743890A120070117; 2007
   Google Scholar
• Torrens-Jover A, Yenes-Minguez S. Preparation of octahydropentalene-substituted pyrazoline derivatives as cannabinoid receptor modulators. PCT Int Appl. WO2007009722A120070125; 2007
   Google Scholar
• Torrens-Jover A, Yenes-Minguez S. Preparation of cycloalkane-substituted pyrazoline derivatives as cannabinoid receptor modulators. PCT Int Appl. WO2007009724A220070125; 2007
   Google Scholar
• Torrens-Jover A, Yenes-Minguez S. Prodrugs of pyrazoline compounds as CB1-receptor antagonists, their preparation and use as medicaments. PCT Int Appl. WO2007009720A220070125; 2007
   Google Scholar
• Yenes-Minguez S, Torrens-Jover A. Preparation and anti-tumor analysis of 4-substituted 1H-pyrazolines for the treatment or prophylaxis of human cancers. Span ES2341522A120100621; 2010
   Google Scholar
• Havrylyuk D, Zimenkovsky B, Vasylenko O, Synthesis of novel thiazolone-based compounds containing pyrazoline moiety and evaluation of their anticancer activity. Eur J Med Chem 2009;44:1396-404
   PubMed Web of Science ®Google Scholar
• Bhat BA, Dhar KL, Puri SC, Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents. Bioorg Med Chem Lett 2005;15:3177-80
   PubMed Web of Science ®Google Scholar
• Shaharyar M, Abdullah MM, Bakht MA, Majeed J. Pyrazoline bearing benzimidazoles: search for anticancer agent. Eur J Med Chem 2010;45:114-19
   PubMed Web of Science ®Google Scholar
• Manna F, Chimenti F, Bolasco A, Inhibition of amine oxidases activity by 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives. Bioorg Med Chem Lett 2002;12:3629-33
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Dorai T, Holland JF, Ohnuma T. Reversal of drug-sensitivity in multidrug-resistant tumor-cells by an MDR1 (Pgy1) Ribozyme. Cancer Res 1994;54:1271-5
   PubMed Web of Science ®Google Scholar
• Johnson M, Younglove B, Lee L, Design, synthesis, and biological testing of pyrazoline derivatives of combretastatin-A4. Bioorg Med Chem Lett 2007;17:5897-901
   PubMed Web of Science ®Google Scholar
• Roecker AJ, Coleman PJ, Mercer SP, Kinesin spindle protein (KSP) inhibitors. Part 8: design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett 2007;17:5677-82
   PubMed Web of Science ®Google Scholar
• Rostom SAF. Synthesis and in vitro antitumor evaluation of some indeno[1,2-c]-pyrazol(in)es substituted with sulfonamide, sulfonylurea(-thiourea) pharmacophores, and some derived thiazole ring systems. Bioorg Med Chem 2006;14:6475-85
   PubMed Web of Science ®Google Scholar
• Coleman PJ, Mercer SP, Roecker AJ. Preparation of pyrazole derivatives as mitotic kinesin inhibitors. PCT Int Appl. WO2006068933A220060629; 2006
   Google Scholar
• Breslin MJ, Coleman PJ, Cox CD, 4,5-Dihydro-1H-pyrazole derivatives useful as mitotic kinesin inhibitors, and their pharmaceutical compositions and use in the treatment of cancer. PCT Int Appl. WO2003079973A220031002; 2003
   Google Scholar
• Villavicencio EH, Yoon JW, Frank DJ, Cooperative E-box regulation of human GLI1 by TWIST and USF. Genesis 2002;32:247-58
   PubMedGoogle Scholar
• Mazumdar T, DeVecchio J, Agyeman A, Blocking hedgehog survival signaling at the level of the GLI genes induces DNA damage and extensive cell death in human colon carcinoma cells. Cancer Res 2011;71:5904-14
   PubMed Web of Science ®Google Scholar
• He B, Fujii N, You L, Dihydropyrazolecarboxamides and their preparation, pharmaceutical compositions and use in the targeting GLI proteins in human cancer by small molecules. US7714014B220100511; 2010
   Google Scholar
• He B, Fujii N, You L, Dihydropyrazolecarboxamides and their preparation, pharmaceutical compositions and use in the targeting GLI proteins in human cancer by small molecules. Int Appl. WO2007067814A220070614; 2007
   Google Scholar
• Havrylyuk D, Kovach N, Zimenkovsky B, Synthesis and anticancer activity of isatin-based pyrazolines and thiazolidines conjugates. Arch Pharm (Weinheim) 2011;344:514-22
   PubMed Web of Science ®Google Scholar
• Buske C, Becker D, FeuringBuske M, TGF-beta inhibits growth and induces apoptosis in leukemic B cell precursors. Leukemia 1997;11:386-92
   PubMed Web of Science ®Google Scholar
• Jang CW, Chen CH, Chen CC, TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase. Nat Cell Biol 2002;4:51-8
   PubMed Web of Science ®Google Scholar
• Schlapbach R, Spanaus KS, Malipiero U, TGF-beta induces the expression of the FLICE-inhibitory protein and inhibits Fas-mediated apoptosis of microglia. Eur J Immunol 2000;30:3680-8
   PubMedGoogle Scholar
• Totth A, Sebestyen A, Barna G, TGF-beta 1 induces caspase-dependent but death-receptor independent apoptosis in lymphoid cells. Anticancer Res 2001;21:1207-12
   PubMed Web of Science ®Google Scholar
• Sawyer JS, Beight DW, Ciapetti P, Preparation of substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF-beta signal transduction inhibitors. PCT Int Appl. WO2002094833A120021128; 2002
   Google Scholar
• Ozdemir Z, Kandilci HB, Gumusel B, Synthesis and studies on antidepressant and anticonvulsant activities of some 3-(2-furyl)-pyrazoline derivatives. Eur J Med Chem 2007;42:373-9
   PubMed Web of Science ®Google Scholar
• Singh SP, Chaudhari A, Barthwal JP, Parmar SS. Anticonvulsant activity and selective-inhibition of nicotinamide adenine dinucleotide-dependent oxidations by 1,3,5-Trisubstituted Pyrazolines. J Pharm Sci 1974;63:1948-50
   PubMedGoogle Scholar
• Shishikura J-I, Inami H, Kaku H, Preparation of acylazole derivatives as kainic acid neurocytotoxicity inhibitors. PCT Int Appl. WO2001032173A120010510; 2001
   Google Scholar
• Torrens-Jover A, Mas Prio J. Quaternary ammonium salts of substituted pyrazoline compounds, their preparation and use as medicaments. PCT Int Appl. WO2007009697A120070125; 2007
   Google Scholar
• Palaska E, Aytemir M, Uzbay IT, Erol D. Synthesis and antidepressant activities of some 3,5-diphenyl-2-pyrazolines. Eur J Med Chem 2001;36:539-43
   PubMed Web of Science ®Google Scholar
• Prasad YR, Rao AL, Prasoona L, Synthesis and antidepressant activity of some 1,3,5-triphenyl-2-pyrazolines and 3-(2''-hydroxynaphthalen-1''-yl)-1,5-diphenyl-2-pyrazolines. Bioorg Med Chem Lett 2005;15:5030-4
   PubMed Web of Science ®Google Scholar
• Chimenti F, Fioravanti R, Bolasco A, Synthesis, molecular modeling studies and selective inhibitory activity against MAO of N1-propanoyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives. Eur J Med Chem 2008;43:2262-7
   PubMed Web of Science ®Google Scholar
• Henkel V, Mergl R, Hegerl U. Atypical depression: is there still evidence for superiority of MAO-inhibitors'? Eur Psychiatry 2005;20:S134
   Google Scholar
• Enserink M. Drug therapies for depression: from MAO inhibitors to substance P. Science 1999;284:238-40
   PubMed Web of Science ®Google Scholar
• Murasaki M. The role of MAO inhibitors on the treatment of depression. Jpn J Neuropsychopharmacol 1997;19:685-700
   Google Scholar
• Amrein R, Uchida C, Stabl M. Efficacy of reversible inhibitors of MAO-A (Rima) in various forms of depression. Int Congr Ser 1991;968:850-4
   Google Scholar
• Larsen JK. The concept of atypical depression and its relation to successful treatments with MAO-Inhibitors. Psychopharmacology (Berl) 1991;103:B6-B
   PubMedGoogle Scholar
• Nolen WA, Vandeputte JJ, Dijken WA, Treatment strategy in depression. 2. MAO inhibitors in depression resistant to cyclic antidepressants - 2 controlled crossover studies with tranylcypromine versus L-5-Hydroxytryptophan and Nomifensine. Acta Psychiatr Scand 1988;78:676-83
   PubMed Web of Science ®Google Scholar
• Haffmans J, Nolen WA, Vanderham E. MAO-inhibitors and sleep in major depression. Pharmacopsychiatry 1988;21:61
   Google Scholar
• Davis JM, Janicak PG, Bruninga K. The efficacy of MAO inhibitors in depression – a metaanalysis. Psychiatr Annu 1987;17:825-31
   Google Scholar
• Raskin DE. MAO inhibitors in chronic pain and depression. J Clin Psychiatr 1982;43:122
   PubMedGoogle Scholar
• Abdala EN. Combination of tricyclic anti-depressants and MAO inhibitors in treatment of depression. Acta Psiquiat Psicol 1975;21:52-5
   PubMedGoogle Scholar
• Purgyi P. Correlation between glucose-tolerance and depression and its treatment with Mao inhibitors and lithium salts. Nervenarzt 1972;43:379-82
   PubMedGoogle Scholar
• Gokhan-Kelekci N, Koyunoglu S, Yabanoglu S, New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. Bioorg Med Chem 2009;17:675-89
   PubMed Web of Science ®Google Scholar
• Gokhan-Kelekci N, Yabanoglu S, Kupeli E, A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics. Bioorg Med Chem 2007;15:5775-86
   PubMed Web of Science ®Google Scholar
• Lensch K, Fuchs G, Boning J, Milech U. A clinical-study of the selective MAO-A inhibitor Moclobemide (RO11-1163) – a comparison of 2 different dosages with particular reference to platelet Mao-activity and urinary Mhpg-excretion. Int Clin Psychopharm 1987;2:165-71
   PubMedGoogle Scholar
• Kaplancikli ZA, Ozdemir A, Turan-Zitouni G, New pyrazoline derivatives and their antidepressant activity. Eur J Med Chem 2010;45:4383-7
   PubMed Web of Science ®Google Scholar
• Jayaprakash V, Sinha BN, Ucar G, Ercan A. Pyrazoline-based mycobactin analogues as MAO-inhibitors. Bioorg Med Chem Lett 2008;18:6362-8
   PubMedGoogle Scholar
• Chimenti F, Bizzarri B, Manna F, Synthesis and in vitro selective anti-Helicobacter pylori activity of pyrazoline derivatives. Bioorg Med Chem Lett 2005;15:603-7
   PubMed Web of Science ®Google Scholar
• Chimenti F, Carradori S, Secci D, Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives. Eur J Med Chem 2010;45:800-4
   PubMedGoogle Scholar
• Barsoum FF, Girgis AS. Facile synthesis of bis(4,5-dihydro-1H-pyrazole-1-carboxamides) and their thio-analogues of potential PGE(2) inhibitory properties. Eur J Med Chem 2009;44:2172-7
   PubMedGoogle Scholar
• Coceani F, Bishai I, Hynes N, Prostaglandin-E2 as a central messenger of fever - mechanism of formation. News Trend L 1989;3:183-6
   Google Scholar
• Coceani F, Bishai I, Lees J, Sirko S. Prostaglandin-E2 in the pathogenesis of Pyrogen fever - validation of an intermediary role. Adv Prostaglandins Thromb L 1989;19:394-7
   PubMedGoogle Scholar
• Rotondo D, Abul HT, Milton AS, Davidson J. Pyrogenic immunomodulators increase the level of prostaglandin-E2 in the blood simultaneously with the onset of fever. Eur J Pharmacol 1988;154:145-52
   PubMedGoogle Scholar
• Barsoum FF, Hosni HM, Girgis AS. Novel bis(1-acyl-2-pyrazolines) of potential anti-inflammatory and molluscicidal properties. Bioorg Med Chem 2006;14:3929-37
   PubMed Web of Science ®Google Scholar
• Amir M, Kumar H, Khan SA. Synthesis and pharmacological evaluation of pyrazoline derivatives as new anti-inflammatory and analgesic agents. Bioorg Med Chem Lett 2008;18:918-22
   PubMed Web of Science ®Google Scholar
• Rathish IG, Javed K, Ahmad S, Synthesis and antiinflammatory activity of some new 1,3,5-trisubstituted pyrazolines bearing benzene sulfonamide. Bioorg Med Chem Lett 2009;19:255-8
   PubMed Web of Science ®Google Scholar
• Rani P, Srivastava VK, Kumar A. Synthesis and antiinflammatory activity of heterocyclic indole derivatives. Eur J Med Chem 2004;39:449-52
   PubMed Web of Science ®Google Scholar
• Girisha KS, Kalluraya B, Narayana V, Padmashree P. Synthesis and pharmacological study of 1-acetyl/propyl-3-aryl-5-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-2-pyrazoline. Eur J Med Chem 2010;45:4640-4
   PubMed Web of Science ®Google Scholar
• Reddy MVR, Billa VK, Pallela VR, Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl) 3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitor. Bioorg Med Chem 2008;16:3907-16
   PubMed Web of Science ®Google Scholar
• Khode S, Maddi V, Aragade P, Synthesis and pharmacological evaluation of a novel series of 5-(substituted) aryl-3-(3-coumarinyl)-1-phenyl-2-pyrazolines as novel anti-inflammatory and analgesic agents. Eur J Med Chem 2009;44:1682-8
   PubMed Web of Science ®Google Scholar
• Shoman ME, Abdel-Aziz M, Aly OM, Synthesis and investigation of anti-inflammatory activity and gastric ulcerogenicity of novel nitric oxide-donating pyrazoline derivatives. Eur J Med Chem 2009;44:3068-76
   PubMedGoogle Scholar
• Kaplancikli ZA, Turan-Zitouni G, Ozdemir A, Synthesis and antinociceptive activities of some pyrazoline derivatives. Eur J Med Chem 2009;44:2606-10
   PubMed Web of Science ®Google Scholar
• Godoy MCM, Fighera MR, Souza FR, alpha(2)-adrenoceptors and 5-HT receptors mediate the antinociceptive effect of new pyrazolines, but not of dipyrone. Eur J Pharmacol 2004;496:93-7
   PubMedGoogle Scholar
• Ozdemir A, Turan-Zitouni G, Kaplancikli ZA, Synthesis and antimicrobial activity of 1-(4-aryl-2-thiazolyl)-3-(2-thienyl)-5-aryl-2-pyrazoline derivatives. Eur J Med Chem 2007;42:403-9
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab BF, Abdel-Aziz HA, Ahmed EM. Synthesis and antimicrobial evaluation of 1-(benzofuran-2-yl)-4-nitro-3-arylbutan-1-ones and 3-(benzofuran-2-yl)-4,5-dihydro-5-aryl-1-[4-(aryl)-1,3-thiazol-2-yl]-1H-pyrazoles. Eur J Med Chem 2009;44:2632-5
   PubMed Web of Science ®Google Scholar
• Abunada NM, Hassaneen HM, Kandile NG, Miqdad OA. Synthesis and biological activity of some new pyrazoline and pyrrolo[3,4-c]pyrazole-4,6-dione derivatives: Reaction of nitrilimines with some dipolarophiles. Molecules 2008;13:1011-24
   PubMedGoogle Scholar
• Bhatt AH, Parekh HH, Parikh KA, Parikh AR. Synthesis of pyrazolines and cyanopyridines as potential antimicrobial agents. Indian J Chem B 2001;40:57-61
   Google Scholar
• Udupi RH, Kushnoor AS, Bhat AR. Synthesis and biological evaluation of certain pyrazoline derivatives of 2-[6-methoxy naphthyl]-propionic acid (Naproxen). Indian J Heterocyclic Chem 1998;8:63-6
   Web of Science ®Google Scholar
• Bharmal FM, Kaneriya DJ, Parekh HH. Synthesis of some pyrazoline derivatives as biologically active agents. Indian J Heterocyclic Chem 2001;10:189-92
   Web of Science ®Google Scholar
• Basawaraj R, Yadav B, Sangapure SS. Synthesis of some 1H-pyrazolines bearing benzofuran as biologically active agents. Indian J Heterocyclic Chem 2001;11:31-4
   Web of Science ®Google Scholar
• Desai J, Nair KB, Misra AN. Synthesis and antimicrobial activities of some new pyrazolines phenyl pyrazolines, flavanones and related compounds. Indian J Heterocyclic Chem 2001;10:261-6
   Google Scholar
• Jamode VS, Chandak HS, Bhagat PR, Tambekar DH. Synthesis and antimicrobial evaluation of some 1-isonicotinoyl/carboxamido-2-pyrazolines. Indian J Heterocyclic Chem 2003;12:323-6
   Google Scholar
• Karthikeyan MS, Holla BS, Kumari NS. Synthesis and antimicrobial studies on novel chloro-fluorine containing hydroxy pyrazolines. Eur J Med Chem 2007;42:30-6
   PubMed Web of Science ®Google Scholar
• Mogilaiah K, Sakram B. Synthesis and antibacterial activities of 1,3,4-oxadiazole and pyrazoline derivatives containing 1,8-naphthyridine moiety. Indian J Heterocyclic Chem 2004;13:289-92
   Google Scholar
• Vijayvergiya D, Kothari S, Verma BL. Synthesis and biological activity of some new 3,5-diaryl-1-phenyl/isonicotinoyl-2-pyrazolines and 3,5-diaryl-6-carbethoxy cyclohexenone derivatives. Indian J Heterocyclic Chem 2003;13:105-10
   Google Scholar
• Waheed A, Khan SA. Synthesis of certain substituted 1,2 pyrazolines from nalidixic acid as antibacterial and analgesic agents. Indian J Heterocyclic Chem 2001;11:59-62
   Google Scholar
• Stirrett KL, Ferreras JA, Jayaprakash V, Small molecules with structural similarities to siderophores as novel antimicrobials against Mycobacterium tuberculosis and Yersinia pestis. Bioorg Med Chem Lett 2008;18:2662-8
   PubMed Web of Science ®Google Scholar
• Shenoy GG, Bhat AR, Bhat GV, Kotian M. Synthesis and antimicrobial activities of 1,3,5 trisubstituted 2-pyrazolines. Indian J Heterocyclic Chem 2001;10:197-200
   Web of Science ®Google Scholar
• Shaharyar M, Siddiqui AA, Ali MA, Synthesis and in vitro antimycobacterial activity of N-1-nicotinoyl-3-(4'-hydroxy-3'-methylphenyl)-5-[(sub)phenyl]-2-pyrazolines. Bioorg Med Chem Lett 2006;16:3947-9
   PubMed Web of Science ®Google Scholar
• Mamolo MG, Zampieri D, Falagiani V, Synthesis and antimycobacterial activity of 5-aryl-1-isonicotinoyl-3-(pyridin-2-yl)-4,5-dihydro-1H-pyrazole derivatives. Farmaco 2001;56:593-9
   PubMedGoogle Scholar
• Ozdemir A, Turan-Zitouni G, Kaplancikli ZA. Novel analogues of 2-Pyrazoline: synthesis, characterization, and antimycobacterial evaluation. Turk J Chem 2008;32:529-38
   Google Scholar
• Guardiola-Diaz HM, Foster LA, Mushrush D, Vaz ADN. Azole-antifungal binding to a novel cytochrome P450 from Mycobacterium tuberculosis: implications for treatment of tuberculosis. Biochem Pharmacol 2001;61:1463-70
   PubMed Web of Science ®Google Scholar
• Zampieri D, Mamolo MG, Laurini E, Antifungal and antimycobacterial activity of 1-(3,5-diaryl-4,5dihydro-1H-pyrazol-4-yl)-1H-imidazole derivatives. Bioorg Med Chem 2008;16:4516-22
   PubMed Web of Science ®Google Scholar
• Kini SG, Bhat AR, Bryant B, Synthesis, antitubercular activity and docking study of novel cyclic azole substituted diphenyl ether derivatives. Eur J Med Chem 2009;44:492-500
   PubMed Web of Science ®Google Scholar
• Ali MA, Shaharyar M, Siddiqui AA. Synthesis, structural activity relationship and anti-tubercular activity of novel pyrazoline derivatives. Eur J Med Chem 2007;42:268-75
   PubMed Web of Science ®Google Scholar
• Babu VH, Manna SK, Srinivasan SKK, Bhat GV. Synthesis and biological evaluation of 1,3,5-trisubstituted pyrazolines bearing benzofuran. Indian J Heterocyclic Chem 2004;13:253-6
   Google Scholar
• Hayat F, Salahuddin A, Umar S, Azam A. Synthesis, characterization, antiamoebic activity and cytotoxicity of novel series of pyrazoline derivatives bearing quinoline tail. Eur J Med Chem 2010;45:4669-75
   PubMedGoogle Scholar
• Budakoti A, Bhat AR, Athar F, Azam A. Syntheses and evaluation of 3-(3-bromo phenyl)-5-phenyl-1-(thiazolo[4,5-b]quinoxaline-2-yl)-2-pyrazoline derivatives. Eur J Med Chem 2008;43:1749-57
   PubMed Web of Science ®Google Scholar
• Budakoti A, Abid M, Azam A. Syntheses, characterization and in vitro antiamoebic activity of new Pd(II) complexes with 1-N-substituted thiocarbamoyl-3,5-diphenyl-2-pyrazoline derivatives. Eur J Med Chem 2007;42:544-51
   PubMed Web of Science ®Google Scholar
• Husain K, Abid M, Azam A. Novel Pd(II) complexes of 1-N-substituted 3-phenyl-2-pyrazoline derivatives and evaluation of antiamoebic activity. Eur J Med Chem 2008;43:393-403
   PubMedGoogle Scholar
• Abid M, Bhat AR, Athar F, Azam A. Synthesis, spectral studies and antiamoebic activity of new 1-N-substituted thiocarbamoyl-3-phenyl-2-pyrazolines. Eur J Med Chem 2009;44:417-25
   PubMedGoogle Scholar
• Abid M, Azam A. Synthesis and antiamoebic activities of 1-N-substituted cyclised pyrazoline analogues of thiosemicarbazones. Bioorg Med Chem 2005;13:2213-20
   PubMed Web of Science ®Google Scholar
• Asha B, Mohammad A, Amir A. Synthesis and antiamoebic activity of new 1-N-substituted thiocarbamoyl-3,5-diphenyl-2-pyrazoline derivatives and their Pd(II) complexes. Eur J Med Chem 2006;41:63-70
   PubMedGoogle Scholar
• Bhat AR, Athar F, Azam A. Bis-pyrazolines: synthesis, characterization and antiamoebic activity as inhibitors of growth of Entamoeba histolytica. Eur J Med Chem 2009;44:426-31
   PubMed Web of Science ®Google Scholar
• Du X, Guo C, Hansell E, Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J Med Chem 2002;45:2695-707
   PubMed Web of Science ®Google Scholar
• Seebacher W, Belaj F, Saf R, New 1,3-Thiazoles and 1,3-Thiazines from 1-Thiocarbamoylpyrazoles. Monatsh Chem 2003;134:1623-8
   Google Scholar
• El-Sabbagh OI, Baraka MM, Ibrahim SM, Synthesis and antiviral activity of new pyrazole and thiazole derivatives. Eur J Med Chem 2009;44:3746-53
   PubMed Web of Science ®Google Scholar
• Torrens-Jover A. Substituted pyrazoline compounds with ACAT inhibition activity, their preparation and use as medicaments in the treatment of dyslipidemia. PCT Int Appl. WO2008087030A120080724; 2008
   Google Scholar
• Yenes-Minguez S, Torrens-Jover A. Substituted pyrazoline compounds with ACAT inhibition activity and their preparation, pharmaceutical compositions and use in treatment of dyslipidemia. PCT Int Appl. WO2008087029A120080724; 2008
   Google Scholar
• Yar MS, Bakht MA, Siddiqui AA, Synthesis and evaluation of in vitro antiviral activity of novel phenoxy acetic acid derivatives. J Enzyme Inhib Med Chem 2009;24:876-82
   PubMedGoogle Scholar
• Puig-Basagoiti F, Tilgner M, Forshey BM, Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob Agents Chemother 2006;50:1320-9
   PubMedGoogle Scholar
• Goodell JR, Puig-Basagoiti F, Forshey BM, Identification of compounds with anti-West Nile Virus activity. J Med Chem 2006;49:2127-37
   PubMed Web of Science ®Google Scholar
• Liang P-H, Ku C-C, Liu H-K, Pyrazole derivatives for preventing and treating diseases caused by picornavirus and coronavirus. Repub Korean Kongkae Taeho Kongbo. KR2010066142A20100617; 2010
   Google Scholar
• Silver KS, Soderlund DM. Action of pyrazoline-type insecticides at neuronal target sites. Pest Biochem Phys 2005;81:136-43
   Google Scholar
• Turan-Zitouni G, Chevallet P, Kilic FS, Erol K. Synthesis of some thiazolyl-pyrazoline derivatives and preliminary investigation of their hypotensive activity. Eur J Med Chem 2000;35:635-41
   PubMed Web of Science ®Google Scholar
• Li L, Pownall HJ. Regulation of acyl-coenzyme A: cholesterol acyltransferase (ACAT) synthesis, degradation, and translocation by high-density lipoprotein(2) at a low concentration. Arterioscler Thromb Vasc 2000;20:2636-42
   PubMedGoogle Scholar
• Jeong TS, Kim KS, An SJ, Novel 3,5-diaryl pyrazolines as human acyl-CoA: cholesterol acyltransferase inhibitors. Bioorg Med Chem Lett 2004;14:2715-17
   PubMed Web of Science ®Google Scholar
• Yenes-Minguez S, Torrens-Jover A. Substituted pyrazoline compounds with ACAT inhibition activity and their preparation, pharmaceutical compositions and use in treatment of dyslipidemia. Eur Pat Appl. EP1947087A120080723; 2008
   Google Scholar
• Camacho ME, Leon J, Entrena A, 4,5-Dihydro-1H-pyrazole derivatives with inhibitory nNOS activity in rat brain: Synthesis and structure-activity-relationships. J Med Chem 2004;47:5641-50
   PubMedGoogle Scholar
• Carrion MD, Cara LCL, Camacho ME, Pyrazoles and pyrazolines as neural and inducible nitric oxide synthase (nNOS and NOS) potential inhibitors (III). Eur J Med Chem 2008;43:2579-91
   PubMedGoogle Scholar
• Babu VH, Sridevi C, Joseph A, Srinivasan K. Synthesis and biological evaluation of some novel pyrazolines. Indian J Pharm Sci 2007;69:470-3
   Google Scholar
• Zhang XQ, Li XJ, Allan GF, Design, synthesis, and in vivo SAR of a novel series of pyrazolines as potent selective androgen receptor modulators. J Med Chem 2007;50:3857-69
   PubMed Web of Science ®Google Scholar
• Jones DG, Liang X, Stewart EL, Discovery of non-steroidal mifepristone mimetics: pyrazoline-based PR antagonists. Bioorg Med Chem Lett 2005;15:3203-6
   PubMed Web of Science ®Google Scholar
• Amr AEE, Abdel-Latif NA, Abdalla MM. Synthesis and antiandrogenic activity of some new 3-substituted androstano[17,16-c]-5'-aryl-pyrazoline and their derivatives. Bioorg Med Chem 2006;14:373-84
   PubMedGoogle Scholar
• Fisas-Escasany MA, Buschmann HH. Preparation of substituted pyrazoline for use in combination therapy with at least one antidiabetic agent. Span. ES2328653A120091116; 2009
   Google Scholar
• Fisas-Escasany MA, Buschmann HH. Preparation of substituted pyrazoline for use in combination therapy with at least one antidiabetic agent. Eur Pat Appl. EP1946778A120080723; 2008
   Google Scholar
• Olsson R. A combinatorial scaffold approach towards the pharmacophores of ligands to urotensin II and somatostatin 5 receptors. PCT Int Appl. WO2004073642A220040902; 2004
   Google Scholar